Estrella Immunopharma Inc...

NASDAQ: ESLA · Real-Time Price · USD
0.94
0.11 (12.68%)
At close: Jun 04, 2025, 3:59 PM
0.95
0.27%
After-hours: Jun 04, 2025, 05:37 PM EDT

Company Description

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States.

The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia.

It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.

Estrella Immunopharma, Inc. is based in EmeryVille, California.

Estrella Immunopharma Inc.
Estrella Immunopharma Inc. logo
Country United States
IPO Date Sep 14, 2021
Industry Biotechnology
Sector Healthcare
Employees n/a
CEO Dr. Cheng Liu Ph.D.

Contact Details

Address:
5858 Horton Street
EmeryVille, California
United States
Website https://www.estrellabio.com

Stock Details

Ticker Symbol ESLA
Exchange NASDAQ
Fiscal Year July - June
Reporting Currency USD
CIK Code 0001844417
CUSIP Number 297584104
ISIN Number US2975841048
Employer ID 00-0000000
SIC Code 6770

Key Executives

Name Position
Dr. Cheng Liu Ph.D. Chief Executive Officer, President & Director
Jiandong Xu Chief Financial Officer

Latest SEC Filings

Date Type Title
Jun 03, 2025 8-K Current Report
May 29, 2025 8-K Current Report
May 14, 2025 10-Q Quarterly Report
May 02, 2025 8-K Current Report
Mar 25, 2025 10-KT Filing
Feb 21, 2025 8-K Current Report
Feb 20, 2025 8-K Current Report
Feb 14, 2025 4 Filing
Feb 14, 2025 4 Filing
Dec 23, 2024 S-8 Filing